Antimicrobial resistance : What does medicine quality have to do with it ?

[1]  A. Attaran,et al.  Poor-Quality Drugs and Global Trade: A Pilot Study , 2014, American Journal of Health Economics.

[2]  P. Newton,et al.  A Repeat Random Survey of the Prevalence of Falsified and Substandard Antimalarials in the Lao PDR: A Change for the Better , 2015, The American journal of tropical medicine and hygiene.

[3]  Act Consortium Drug Quality Project Team And The I.  Quality of Artemisinin-Containing Antimalarials in Tanzania's Private Sector—Results from a Nationally Representative Outlet Survey , 2015, The American journal of tropical medicine and hygiene.

[4]  A. Attaran.  Stopping Murder by Medicine: Introducing the Model Law on Medicine Crime , 2015, The American journal of tropical medicine and hygiene.

[5]  Matthew E. Falagas,et al.  Substandard/Counterfeit Antimicrobial Drugs , 2015, Clinical Microbiology Reviews.

[6]  J. Roberts,et al.  Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development , 2015, Seminars in Respiratory and Critical Care Medicine.

[7]  S. Bagcchi.  Indian generic drugs debate heats up , 2014, The Lancet.

[8]  I. Choonara,et al.  Quality of medicines in Canada: a retrospective review of risk communication documents (2005–2013) , 2014, BMJ Open.

[9]  F. Schifano,et al.  A systematic review of counterfeit and substandard medicines in field quality surveys , 2014 .

[10]  P. Newton,et al.  Falsified medicines in Africa: all talk, no action. , 2014, The Lancet. Global health.

[11]  A. Stergachis,et al.  Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries , 2014, PloS one.

[12]  Laura Krech,et al.  Cambodian Ministry of Health Takes Decisive Actions in the Fight Against Substandard and Counterfeit Medicines , 2014 .

[13]  Atholl Johnston,et al.  Substandard drugs: a potential crisis for public health , 2013, British journal of clinical pharmacology.

[14]  Imti Choonara,et al.  Substandard and counterfeit medicines: a systematic review of the literature , 2013, BMJ Open.

[15]  I. Choonara,et al.  Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001–2011) , 2013, BMJ Open.

[16]  C. Chaccour,et al.  Travel and fake artesunate: a risky business , 2012, The Lancet.

[17]  P. Toutain,et al.  Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. , 2011, The Journal of antimicrobial chemotherapy.

[18]  Paul N. Newton,et al.  Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries. , 2011, The Analyst.

[19]  R. Jeffery,et al.  Trust and the regulation of pharmaceuticals: South Asia in a globalised world , 2011, Globalization and health.

[20]  G. Jin,et al.  Does Price Reveal Poor-Quality Drugs? Evidence from 17 Countries , 2011, Journal of health economics.

[21]  R. Malpani,et al.  Eye on the Ball: Medicine regulation - not IP enforcement - can best deliver quality medicine , 2011 .

[22]  E. Johansson,et al.  Antibiotic use, resistance development and environmental factors: a qualitative study among healthcare professionals in Orissa, India , 2010, BMC public health.

[23]  R. Maude,et al.  Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance , 2009, Malaria Journal.

[24]  M. Rowland,et al.  Epidemic of Plasmodium falciparum Malaria Involving Substandard Antimalarial Drugs, Pakistan, 2003 , 2009, Emerging infectious diseases.

[25]  Janet Bumpas,et al.  Exploratory Study on Active Pharmaceutical Ingredient Manufacturing for Essential Medicines , 2009 .

[26]  Christina Y Hampton,et al.  A stratified random survey of the proportion of poor quality oral artesunate sold at medicine outlets in the Lao PDR – implications for therapeutic failure and drug resistance , 2009, Malaria Journal.

[27]  Roger Bate,et al.  Pilot Study Comparing Technologies to Test for Substandard Drugs in Field Settings , 2009 .

[28]  N. Ford,et al.  Substandard medicines in resource‐poor settings: a problem that can no longer be ignored , 2008, Tropical medicine & international health : TM & IH.

[29]  P. Newton,et al.  Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. , 2008, The American journal of tropical medicine and hygiene.

[30]  K. Stȩpniewska,et al.  Pharmacokinetic Determinants of the Window of Selection for Antimalarial Drug Resistance , 2008, Antimicrobial Agents and Chemotherapy.

[31]  O. Shakoor,et al.  Pharmacopoeial quality of drugs supplied by Nigerian pharmacies , 2001, The Lancet.

[32]  P. Ringwald,et al.  False chloroquine resistance in Africa , 1997, The Lancet.

[33]  F. Baquero,et al.  Strategies to minimize the development of antibiotic resistance. , 1997, Journal of chemotherapy.

[34]  M. Kron.  Substandard primaquine phosphate for US Peace Corps personnel , 1996, The Lancet.